Enterocolitis
9
1
1
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
44%
4 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
A Study of SER-155 to Treat Diarrhea in People on Immunotherapy
Probiotics and Post-Pullthrough Hirschsprung's Disease-Associated Enterocolitis
Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff Infection
Impact of Oral Antibiotic Treatment on C. Difficile
Addition of Lactobacillus to Metronidazole in Treatment of CDAD
Identification Genetic, Immunologic and Microbial Markers of Hirschsprung Associated Enterocolitis in Children With Hirschsprung Disease
Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
Fecal Bacterial Flora in Clostridium Difficile-Associated Diarrhea
Effect of Probiotics (Bio-Three) in Children's Enterocolitis